The global bronchodilator market size is projected to expand from USD 38.2 billion in 2024 to USD 67.8 billion by 2034. Sales of bronchodilators are predicted to soar at a CAGR of 5.9% in the estimated period 2024 to 2034. In 2023, the bronchodilator market value totaled USD 36.2 billion and is set to exhibit a y-o-y growth of 5.7% in 2024.
| Attributes | Key Insights |
|---|---|
| Bronchodilator Market Value in 2023 | USD 36.2 billion |
| Estimated Bronchodilator Market Size (2024) | USD 38.2 billion |
| Projected Bronchodilator Market Revenue (2034) | USD 67.8 billion |
| Expected Bronchodilator Market CAGR (2024 to 2034) | 5.9% |
| Market Share of Top 5 Countries | 46.9% |
Bronchodilator Market Overview
Bronchodilators have become highly sought-after medications to treat different respiratory diseases and other medical conditions. This class of drugs is set to aid in relaxing the airway-restricting muscles.
Bronchodilators are expected to be extensively used to reduce pulmonary mucus. Patients with respiratory disorders are recommended to use inhalers or nebulizers to administer these drugs.
Bronchodilators used for inhalation also affect mucociliary clearance. They are set to be used in the treatment of obstructive lung disorders (bronchi), such as asthma, and chronic obstructive pulmonary disorders (COPD) by loosening the muscles in the lungs and widening the airways. Hence, the growing prevalence of these diseases will likely drive demand for bronchodilators.
Short-acting and long-acting bronchodilators are the two types of bronchodilators used by patients suffering from respiratory disease. To treat respiratory conditions, bronchodilators come in a range of forms, including sympathomimetic, anticholinergic, phosphodiesterase inhibitors, and combination drugs. Depending on the method of administration, these types are available in different forms, such as inhalers, tablets, liquids, and injectables.
Other factors influencing market growth include:
As per the latest bronchodilator industry analysis, global bronchodilator sales grew at a CAGR of 5.0% between 2019 and 2023. The market value for bronchodilators was about 43.3% of the respiratory diseases drug market in 2022, which was valued at USD 79.8 billion.
| Historical CAGR (2019 to 2023) | 5.0% |
|---|---|
| Forecast CAGR (2024 to 2034) | 5.9% |
The main factor propelling the growth of the bronchodilator industry is the rising prevalence of respiratory illnesses, including asthma and chronic obstructive pulmonary disease (COPD), worldwide. Similarly, rising disposable income, a growing geriatric population, and a rise in public awareness of healthcare are all predicted to spur market expansion.
The market is also growing as a result of increased bronchodilator use in the treatment of cystic fibrosis. Subsequently, favorable government initiatives to reduce the burden of respiratory diseases are set to elevate demand for bronchodilators through 2034.
In recent years, there has been a spike in respiratory illnesses such as asthma. For instance, as per the Centers for Disease Control and Prevention (CDC), 1 in 13 individuals have asthma, which results in 9.8 million doctor visits, 188,968 hospital inpatient discharges, and 1.8 million trips to emergency rooms annually.
Over 25 million people in the United States, or 7.7% of adults and 8.4% of children, suffer from asthma, making it a common condition globally. With 8% of the adult population and 12% to 13% of children estimated to have asthma, the United Arab Emirates has a higher reported prevalence of the disease than the United States.
To treat asthma and relieve its symptoms, bronchodilators are set to be frequently used. Hence, the growing prevalence of asthma will play a key role in bolstering sales of bronchodilators.
The market for bronchodilators is expected to see new prospects due to continuous research and development efforts. New drug administration methods are being developed by manufacturers, which is anticipated to increase drug consumption and fuel the global bronchodilator market.
Top bronchodilator manufacturers are investing significantly in developing multiple nebulizer and inhaler types that would give patients convenient access. The development of novel bronchodilators with higher effectiveness and minimal side effects will boost the target market.
Improvements in healthcare structures and increasing government initiatives are expected to boost the market for bronchodilators globally. These factors will create lucrative growth opportunities for bronchodilator manufacturing companies.
Governments worldwide are launching different schemes to reduce the burden of respiratory diseases. Several steps are also taken to make the treatments affordable for everyone and spread awareness about the prevention of diseases. This is predicted to positively impact bronchodilator sales.
The growing incidence of COPD is acting as a catalyst fueling demand for bronchodilators, and the trend is expected to continue through 2034. Subsequently, the introduction of new programs to tackle the COPD burden will likely foster the growth of the bronchodilator industry.
Countries worldwide are launching new programs and initiatives to counter the burden of respiratory diseases. For instance, the COPD National Action Plan was recently launched to reduce COPD burden.
The COPD action plan aims to enhance the prevention, diagnosis, treatment, and management of COPD by enhancing the quality of care provided throughout the healthcare continuum. It strives to help those with COPD, their family members, and their caregivers.
Bronchodilators play an important role in terms of loosening up the muscles that constrict the airways. However, the side effects associated with bronchodilators are the main hindrance to the growth of this market.
Beta-2 agonists such as salbutamol and anticholinergics have several common adverse effects. These include trembling, especially in the hands, nervous tension, headaches, muscular cramps, dry mouth, constipation, difficulty in swallowing (dysphagia), heartburn, and palpitations.
When using an inhaler or nebulizer, patients can aggravate their glaucoma if the anticholinergic medicine gets in their eyes. If theophylline builds up in a patient’s body in excess, it can have negative side effects.
Theophylline side effects are more likely to affect older persons since their livers can be less able to eliminate it from their systems. A quick heartbeat (tachycardia), an irregular heartbeat (arrhythmia), headaches, and difficulty sleeping are a handful of theophylline's negative effects. These factors are expected to limit the growth of the bronchodilator market.
The table below shows the anticipated growth rates of the top countries. The United States, India, and China are expected to record lucrative CAGRs of 6.1%, 6.2%, and 5.3%, respectively, through 2034.
| Countries | CAGR (2023 to 2034) |
|---|---|
| United States | 6.1% |
| Canada | 5.0% |
| China | 5.3% |
| India | 6.2% |
| Germany | 5.1% |
The United States bronchodilator market value totaled USD 9.39 billion in 2023. It accounted for about 25.9% share of the global bronchodilator industry in 2023. Over the forecast period, sales of bronchodilators in the United States are predicted to rise at a 6.1% CAGR.
As per the latest report, the United States is expected to experience significant growth throughout the forecast period. This is attributable to the rising prevalence of COPD and other respiratory diseases, the high demand for breathing disorder medications, and the growing popularity of inhaled bronchodilators.
The increasing prevalence of COPD and asthma is playing a vital role in bolstering sales of bronchodilators in the United States. As per the Centers for Disease Control and Prevention (CDC), chronic lower respiratory disease remained the fourth most common cause of death in the United States in 2021.
More than 15 million people have COPD, and over 150,000 of them die from it each year, or one every four minutes. This is prompting patients suffering from COPD to opt for COPD treatment drugs, including bronchodilators.
Bronchodilators are mainly used as medication for COPD and asthma. They help relax the muscles in the airways and open them up, making breathing easier for patients with asthma and COPD. This is a prime driver boosting the growth of the bronchodilator market in the country.
Germany is set to exhibit a CAGR of 5.1% during the assessment period. It held a value share of about 4.0% in the global bronchodilator industry in 2023. The good healthcare infrastructure and increased awareness among people about hygiene are driving the growth of the bronchodilator market in Germany.
According to the World Health Organization (WHO), Germany is a top global leader in public health, as seen by its global health strategy and programs and the experience, knowledge, and funding it offers to WHO. Due to these reasons, the market for bronchodilators in Germany is increasing.
Growing preference for long-acting bronchodilators is another key factor expected to boost sales in the country. Similarly, rising cases of asthma will improve Germany’s bronchodilator industry share through 2034.
India held a 4.3% share of the worldwide bronchodilator industry in 2023. Over the assessment period, demand for bronchodilators in the country is anticipated to increase at a CAGR of 6.2%.
The increasing burden of non-communicable diseases and government initiatives toward the healthcare sector is expected to drive the growth of the bronchodilator market in India. The government is launching different initiatives and programs to reduce the burden of respiratory diseases.
For instance, in February 2017, the honorable Health and Family Welfare Minister launched the Kerala COPD Prevention and Control Program- ‘SWAAS.’ It is the country's first COPD prevention and control program that can help to tackle the burden of COPD. Such initiatives are creating a favorable environment for the expansion of the bronchodilator market.
Canada’s bronchodilator market size reached over USD 1.6 billion at the end of 2023. For the assessment period, bronchodilator sales in the country are projected to soar at a 5.0% CAGR, making it a lucrative market for companies.
Multiple factors are expected to stimulate growth in Canada’s bronchodilator industry. These include rising incidence of respiratory diseases, favorable government support, and growing adoption of combination therapies.
The cases of respiratory diseases like COPD and asthma are rising dramatically across Canada. This is expected to elevate the demand for bronchodilators as they are often used to treat these respiratory diseases.
China is emerging as a highly lucrative market for bronchodilators across East Asia. This is attributable to factors such as the rising cases of COPD and asthma, increasing awareness about bronchodilators, and the rising popularity of home healthcare.
China’s bronchodilator market size reached USD 2.94 billion in 2023. Demand for bronchodilators in China is predicted to surge at a steady CAGR of 5.3% throughout the forecast period.
Bronchodilators and other airway expansion medications are becoming highly popular among patients and healthcare professionals in China, leading to increased demand for these medications. This is due to the rising awareness about the benefits of these bronchodilators.
Several public health campaigns are being launched in China to educate people about respiratory diseases and their treatment approaches. This is expected to uplift demand for bronchodilators and other related medications, thereby fostering China’s bronchodilator market growth.
The section below shows the phosphodiesterase inhibitor segment dominating the bronchodilator market. It is poised to exhibit a CAGR of 6.2% during the forecast period. By application, the asthma segment is expected to thrive at a 6.6% CAGR.
Based on the route of administration, the oral segment is expected to lead the global bronchodilator industry. It will likely expand at a 6.4% CAGR between 2024 and 2034. By distribution channel, the retail pharmacies segment is anticipated to thrive at a CAGR of 6.0% through 2034.
Market Growth Outlook by Drug Class
| Drug Class | Value CAGR |
|---|---|
| Sympathomimetic | 6.7% |
| Anticholinergics | 5.3% |
| Phosphodiesterase Inhibitor | 6.2% |
| Combination Drugs | 4.9% |
| Others | 5.9% |
Based on drug class, the phosphodiesterase inhibitor segment dominated the global bronchodilator market with a revenue share of 25.6% in 2023. Over the forecast period, demand for phosphodiesterase inhibitors is projected to rise at a CAGR of around 6.2%.
Phosphodiesterase inhibitors have become highly sought-after drugs to treat a variety of respiratory disorders. For instance, they are effective in treating asthma and chronic obstructive pulmonary disease (COPD).
Phosphodiesterase inhibitors work by curbing the breakdown of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP). These molecules are essential for the relaxation of smooth muscles, thereby helping to open up airways and making it easier to breathe.
The growing adoption of phosphodiesterase inhibitors to treat several respiratory diseases is expected to boost the target segment. Key bronchodilator companies are expected to capitalize on this rising demand by releasing new phosphodiesterase inhibitors.
Sympathomimetic drugs, on the other hand, are expected to witness a higher demand in the global market. This is due to their ability to treat different respiratory diseases by mimicking the effects of the sympathetic nervous system. The target segment is set to thrive at a 6.7% CAGR through 2034.
Market Growth Outlook by Application
| Application | Value CAGR |
|---|---|
| Asthma | 6.6% |
| COPD | 5.9% |
| Others | 5.2 |
As per the latest bronchodilator market analysis, asthma is predicted to remain a key revenue-generation segment for manufacturers of bronchodilators. This is due to the rising prevalence of asthma and the growing need for asthma relief medications.
In 2023, the asthma segment accounted for a revenue share of 34.2%. Over the forecast period, the target segment is poised to exhibit a CAGR of 6.6%, owing to the rising prevalence of pediatric asthma cases.
In recent years, there has been a spike in asthma cases worldwide. As per the World Health Organization (WHO), around 262 million people were affected by asthma in 2019, while there were 455000 asthma-related deaths. This is expected to drive the demand for bronchodilators as they relieve asthma symptoms and allow people with asthma to lead a normal life.
Market Growth Outlook by Route of Administration
| Route of Administration | Value CAGR |
|---|---|
| Oral | 6.4% |
| Injection | 5.7% |
| Inhalation | 5.1% |
Orally used bronchodilators held a prominent market share value of 46.5% in 2023 and are expected to rise with a CAGR of 6.4% during the forecast period. This is attributable to the convenience and cost-effectiveness of the orally administered bronchodilators.
Oral bronchodilators remain the preferable route of drug administration owing to their better convenience and inexpensive nature. They tend to be more readily accepted by patients, which promotes greater adherence to prescribed treatment regimens, eventually leading to improved health outcomes.
Market Growth Outlook by Distribution Channel
| Distribution Channel | Value CAGR |
|---|---|
| Retail Pharmacies | 6.0% |
| Hospital Pharmacies | 5.3% |
| E-Commerce | 6.4% |
| Drug Stores | 6.1% |
The retail pharmacies segment accounted for a dominant market share value of 32.4% at the end of 2023. For the projection period, the target segment is anticipated to thrive at a CAGR of 6.0%. This is due to the easy availability of bronchodilators in retail pharmacies.
Retail pharmacies provide a diverse selection of bronchodilators with heavy discounts. As a result, they are becoming an ideal destination for people to purchase bronchodilators. Hence, the growing inclination of patients toward purchasing bronchodilators from retail pharmacies will boost the target segment.
The bronchodilator industry is highly fragmented, with several companies competing for market share. Top manufacturers of bronchodilators are focusing on launching new products to match consumer demand and increase their client base. They are also using strategies such as mergers, acquisitions, partnerships and collaborations, and celebrity endorsements to stay ahead of the competition.
Recent Developments in the Bronchodilator Market
Table 01: Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Table 02: Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application
Table 03: Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Table 04: Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
Table 05: Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
Table 06: North America Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 07: North America Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Table 08: North America Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application
Table 09: North America Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Table 10: North America Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
Table 11: Latin America Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 12: Latin America Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Table 13: Latin America Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application
Table 14: Latin America Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Table 15: Latin America Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
Table 16: Europe Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 17: Europe Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Table 18: Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application
Table 19: Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Table 20: Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
Table 21: East Asia Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 22: East Asia Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Table 23: East Asia Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application
Table 24: East Asia Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Table 25: East Asia Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
Table 26: South Asia Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 27: South Asia Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Table 28: South Asia Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application
Table 29: South Asia Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Table 30: South Asia Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
Table 31: Oceania Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 32: Oceania Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Table 33: Oceania Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application
Table 34: Oceania Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Table 35: Oceania Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
Table 36: Middle East & Africa Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 37: Middle East & Africa Market Value (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Table 38: Middle East & Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application
Table 39: Middle East & Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Table 40: Middle East & Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
Figure 01: Global Market Value (US$ billion) Analysis, 2019 to 2023
Figure 02: Global Market Forecast & Y-o-Y Growth, 2024 to 2034
Figure 03: Global Market Absolute $ Opportunity (US$ billion) Analysis, 2024 to 2034
Figure 04: Global Market Value Share (%) Analysis 2024 and 2034, by Drug Class
Figure 05: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Drug Class
Figure 06: Global Market Attractiveness Analysis 2024 to 2034, by Drug Class
Figure 07: Global Market Value Share (%) Analysis 2024 and 2034, by Application
Figure 08: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Application
Figure 09: Global Market Attractiveness Analysis 2024 to 2034, by Application
Figure 10: Global Market Value Share (%) Analysis 2024 and 2034, by Route of Administration
Figure 11: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Route of Administration
Figure 12: Global Market Attractiveness Analysis 2024 to 2034, by Route of Administration
Figure 13: Global Market Value Share (%) Analysis 2024 and 2034, by Distribution Channel
Figure 14: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Distribution Channel
Figure 15: Global Market Attractiveness Analysis 2024 to 2034, by Distribution Channel
Figure 16: Global Market Value Share (%) Analysis 2024 and 2034, by Region
Figure 17: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Region
Figure 18: Global Market Attractiveness Analysis 2024 to 2034, by Region
Figure 19: North America Market Value (US$ billion) Analysis, 2019 to 2023
Figure 20: North America Market Value (US$ billion) Forecast, 2024 to 2034
Figure 21: North America Market Value Share, by Drug Class (2024 E)
Figure 22: North America Market Value Share, by Application (2024 E)
Figure 23: North America Market Value Share, by Route of Administration (2024 E)
Figure 24: North America Market Value Share, by Distribution Channel (2024 E)
Figure 25: North America Market Value Share, by Country (2024 E)
Figure 26: North America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 27: North America Market Attractiveness Analysis by Application, 2024 to 2034
Figure 28: North America Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 30: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 31: United States Market Value Proportion Analysis, 2024
Figure 32: Global Vs. United States Growth Comparison
Figure 33: United States Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 34: United States Market Share Analysis (%) by Application, 2024 to 2034
Figure 35: United States Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 36: United States Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 37: Canada Market Value Proportion Analysis, 2024
Figure 38: Global Vs. Canada. Growth Comparison
Figure 39: Canada Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 40: Canada Market Share Analysis (%) by Application, 2024 to 2034
Figure 41: Canada Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 42: Canada Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 43: Latin America Market Value (US$ billion) Analysis, 2019 to 2023
Figure 44: Latin America Market Value (US$ billion) Forecast, 2024 to 2034
Figure 45: Latin America Market Value Share, by Drug Class (2024 E)
Figure 46: Latin America Market Value Share, by Application (2024 E)
Figure 47: Latin America Market Value Share, by Route of Administration (2024 E)
Figure 48: Latin America Market Value Share, by Distribution Channel (2024 E)
Figure 49: Latin America Market Value Share, by Country (2024 E)
Figure 50: Latin America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 51: Latin America Market Attractiveness Analysis by Application, 2024 to 2034
Figure 52: Latin America Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 53: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 54: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 55: Mexico Market Value Proportion Analysis, 2024
Figure 56: Global Vs Mexico Growth Comparison
Figure 57: Mexico Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 58: Mexico Market Share Analysis (%) by Application, 2024 to 2034
Figure 59: Mexico Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 60: Mexico Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 61: Brazil Market Value Proportion Analysis, 2024
Figure 62: Global Vs. Brazil. Growth Comparison
Figure 63: Brazil Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 64: Brazil Market Share Analysis (%) by Application, 2024 to 2034
Figure 65: Brazil Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 66: Brazil Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 67: Argentina Market Value Proportion Analysis, 2024
Figure 68: Global Vs Argentina Growth Comparison
Figure 69: Argentina Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 70: Argentina Market Share Analysis (%) by Application, 2024 to 2034
Figure 71: Argentina Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 72: Argentina Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 73: Europe Market Value (US$ billion) Analysis, 2019 to 2023
Figure 74: Europe Market Value (US$ billion) Forecast, 2024 to 2034
Figure 75: Europe Market Value Share, by Drug Class (2024 E)
Figure 76: Europe Market Value Share, by Application (2024 E)
Figure 77: Europe Market Value Share, by Route of Administration (2024 E)
Figure 78: Europe Market Value Share, by Distribution Channel (2024 E)
Figure 79: Europe Market Value Share, by Country (2024 E)
Figure 80: Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 81: Europe Market Attractiveness Analysis by Application, 2024 to 2034
Figure 82: Europe Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 83: Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 84: Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 85: United Kingdom Market Value Proportion Analysis, 2024
Figure 86: Global Vs. United Kingdom Growth Comparison
Figure 87: United Kingdom Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 88: United Kingdom Market Share Analysis (%) by Application, 2024 to 2034
Figure 89: United Kingdom Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 90: United Kingdom Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 91: Germany Market Value Proportion Analysis, 2024
Figure 92: Global Vs. Germany Growth Comparison
Figure 93: Germany Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 94: Germany Market Share Analysis (%) by Application, 2024 to 2034
Figure 95: Germany Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 96: Germany Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 97: Italy Market Value Proportion Analysis, 2024
Figure 98: Global Vs. Italy Growth Comparison
Figure 99: Italy Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 100: Italy Market Share Analysis (%) by Application, 2024 to 2034
Figure 101: Italy Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 102: Italy Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 103: France Market Value Proportion Analysis, 2024
Figure 104: Global Vs France Growth Comparison
Figure 105: France Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 106: France Market Share Analysis (%) by Application, 2024 to 2034
Figure 107: France Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 108: France Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 109: Spain Market Value Proportion Analysis, 2024
Figure 110: Global Vs Spain Growth Comparison
Figure 111: Spain Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 112: Spain Market Share Analysis (%) by Application, 2024 to 2034
Figure 113: Spain Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 114: Spain Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 115: Russia Market Value Proportion Analysis, 2024
Figure 116: Global Vs Russia Growth Comparison
Figure 117: Russia Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 118: Russia Market Share Analysis (%) by Application, 2024 to 2034
Figure 119: Russia Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 120: Russia Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 121: BENELUX Market Value Proportion Analysis, 2024
Figure 122: Global Vs BENELUX Growth Comparison
Figure 123: BENELUX Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 124: BENELUX Market Share Analysis (%) by Application, 2024 to 2034
Figure 125: BENELUX Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 126: BENELUX Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 127: East Asia Market Value (US$ billion) Analysis, 2019 to 2023
Figure 128: East Asia Market Value (US$ billion) Forecast, 2024 to 2034
Figure 129: East Asia Market Value Share, by Drug Class (2024 E)
Figure 130: East Asia Market Value Share, by Application (2024 E)
Figure 131: East Asia Market Value Share, by Route of Administration (2024 E)
Figure 132: East Asia Market Value Share, by Distribution Channel (2024 E)
Figure 133: East Asia Market Value Share, by Country (2024 E)
Figure 134: East Asia Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 135: East Asia Market Attractiveness Analysis by Application, 2024 to 2034
Figure 136: East Asia Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 137: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 138: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 139: China Market Value Proportion Analysis, 2024
Figure 140: Global Vs. China Growth Comparison
Figure 141: China Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 142: China Market Share Analysis (%) by Application, 2024 to 2034
Figure 143: China Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 144: China Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 145: Japan Market Value Proportion Analysis, 2024
Figure 146: Global Vs. Japan Growth Comparison
Figure 147: Japan Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 148: Japan Market Share Analysis (%) by Application, 2024 to 2034
Figure 149: Japan Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 150: Japan Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 151: South Korea Market Value Proportion Analysis, 2024
Figure 152: Global Vs South Korea Growth Comparison
Figure 153: South Korea Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 154: South Korea Market Share Analysis (%) by Application, 2024 to 2034
Figure 155: South Korea Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 156: South Korea Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 157: South Asia Market Value (US$ billion) Analysis, 2019 to 2023
Figure 158: South Asia Market Value (US$ billion) Forecast, 2024 to 2034
Figure 159: South Asia Market Value Share, by Drug Class (2024 E)
Figure 160: South Asia Market Value Share, by Application (2024 E)
Figure 161: South Asia Market Value Share, by Route of Administration (2024 E)
Figure 162: South Asia Market Value Share, by Distribution Channel (2024 E)
Figure 163: South Asia Market Value Share, by Country (2024 E)
Figure 164: South Asia Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 165: South Asia Market Attractiveness Analysis by Application, 2024 to 2034
Figure 166: South Asia Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 167: South Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 168: South Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 169: India Market Value Proportion Analysis, 2024
Figure 170: Global Vs. India Growth Comparison
Figure 171: India Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 172: India Market Share Analysis (%) by Application, 2024 to 2034
Figure 173: India Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 174: India Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 175: Indonesia Market Value Proportion Analysis, 2024
Figure 176: Global Vs. Indonesia Growth Comparison
Figure 177: Indonesia Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 178: Indonesia Market Share Analysis (%) by Application, 2024 to 2034
Figure 179: Indonesia Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 180: Indonesia Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 181: Malaysia Market Value Proportion Analysis, 2024
Figure 182: Global Vs. Malaysia Growth Comparison
Figure 183: Malaysia Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 184: Malaysia Market Share Analysis (%) by Application, 2024 to 2034
Figure 185: Malaysia Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 186: Malaysia Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 187: Thailand Market Value Proportion Analysis, 2024
Figure 188: Global Vs. Thailand Growth Comparison
Figure 189: Thailand Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 190: Thailand Market Share Analysis (%) by Application, 2024 to 2034
Figure 191: Thailand Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 192: Thailand Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 193: Oceania Market Value (US$ billion) Analysis, 2019 to 2023
Figure 194: Oceania Market Value (US$ billion) Forecast, 2024 to 2034
Figure 195: Oceania Market Value Share, by Drug Class (2024 E)
Figure 196: Oceania Market Value Share, by Application (2024 E)
Figure 197: Oceania Market Value Share, by Route of Administration (2024 E)
Figure 198: Oceania Market Value Share, by Distribution Channel (2024 E)
Figure 199: Oceania Market Value Share, by Country (2024 E)
Figure 200: Oceania Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 201: Oceania Market Attractiveness Analysis by Application, 2024 to 2034
Figure 202: Oceania Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 203: Oceania Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 204: Oceania Market Attractiveness Analysis by Country, 2024 to 2034
Figure 205: Australia Market Value Proportion Analysis, 2024
Figure 206: Global Vs. Australia Growth Comparison
Figure 207: Australia Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 208: Australia Market Share Analysis (%) by Application, 2024 to 2034
Figure 209: Australia Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 210: Australia Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 211: New Zealand Market Value Proportion Analysis, 2024
Figure 212: Global Vs New Zealand Growth Comparison
Figure 213: New Zealand Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 214: New Zealand Market Share Analysis (%) by Application, 2024 to 2034
Figure 215: New Zealand Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 216: New Zealand Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 217: Middle East & Africa Market Value (US$ billion) Analysis, 2019 to 2023
Figure 218: Middle East & Africa Market Value (US$ billion) Forecast, 2024 to 2034
Figure 219: Middle East & Africa Market Value Share, by Drug Class (2024 E)
Figure 220: Middle East & Africa Market Value Share, by Application (2024 E)
Figure 221: Middle East & Africa Market Value Share, by Route of Administration (2024 E)
Figure 222: Middle East & Africa Market Value Share, by Distribution Channel (2024 E)
Figure 223: Middle East & Africa Market Value Share, by Country (2024 E)
Figure 224: Middle East & Africa Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 225: Middle East & Africa Market Attractiveness Analysis by Application, 2024 to 2034
Figure 226: Middle East & Africa Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 227: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 228: Middle East & Africa Market Attractiveness Analysis by Country, 2024 to 2034
Figure 229: GCC Countries Market Value Proportion Analysis, 2024
Figure 230: Global Vs GCC Countries Growth Comparison
Figure 231: GCC Countries Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 232: GCC Countries Market Share Analysis (%) by Application, 2024 to 2034
Figure 233: GCC Countries Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 234: GCC Countries Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 235: Turkey Market Value Proportion Analysis, 2024
Figure 236: Global Vs. Turkey Growth Comparison
Figure 237: Turkey Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 238: Turkey Market Share Analysis (%) by Application, 2024 to 2034
Figure 239: Turkey Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 240: Turkey Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 241: South Africa Market Value Proportion Analysis, 2024
Figure 242: Global Vs. South Africa Growth Comparison
Figure 243: South Africa Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 244: South Africa Market Share Analysis (%) by Application, 2024 to 2034
Figure 245: South Africa Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 246: South Africa Market Share Analysis (%) by Distribution Channel, 2024 to 2034
Figure 247: North Africa Market Value Proportion Analysis, 2024
Figure 248: Global Vs North Africa Growth Comparison
Figure 249: North Africa Market Share Analysis (%) by Drug Class, 2024 to 2034
Figure 250: North Africa Market Share Analysis (%) by Application, 2024 to 2034
Figure 251: North Africa Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 252: North Africa Market Share Analysis (%) by Distribution Channel, 2024 to 2034
The global bronchodilator market value totaled USD 36.2 billion in 2023.
The bronchodilator market size is expected to reach USD 38.2 billion in 2024.
By 2034, the global bronchodilator market value is projected to reach USD 67.8 billion.
Demand for bronchodilators is predicted to rise at a 5.9% CAGR through 2034.
High prevalence of lung diseases such as COPD & asthma and new product launches.
North America dominated the global market with a share of 27.5% in 2023.
Sales in Germany are set to expand at a 5.1% CAGR through 2034.
The United States, China, India, Germany, and the United Kingdom.
Abbott Laboratories, AstraZeneca plc., and Boehringer Ingelheim International GmbH.
From 2019 to 2023, the market for bronchodilators expanded at 5.0% CAGR.
India's bronchodilator market is expected to total USD 1.5 billion by 2034.
Bronchodilator demand in China is projected to surge at 5.3% CAGR through 2034.
Cholinergic and adrenergic receptors are the main targets of bronchodilators.
Anticholinergics and sympathomimetic drugs are used as bronchodilators.
Anticholinergics, Theophylline, and beta 2-agonists.
Bronchodilator Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
